Sign in Sign up for free

Last updated: 3 July 2023 at 5:51pm EST

Alfred Kingsley Net Worth




The estimated Net Worth of Alfred D Kingsley is at least $5.85 Million dollars as of 14 June 2023. Mr. Kingsley owns over 30,000 units of Lineage Cell Therapeutics Inc stock worth over $405,875 and over the last 21 years he sold LCTX stock worth over $5,442,001. In addition, he makes $0 as Chairman of the Board at Lineage Cell Therapeutics Inc.

Mr. Kingsley LCTX stock SEC Form 4 insiders trading

Alfred has made over 16 trades of the Lineage Cell Therapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 30,000 units of LCTX stock worth $6,300 on 14 June 2023.

The largest trade he's ever made was selling 344,828 units of Lineage Cell Therapeutics Inc stock on 15 November 2012 worth over $1,000,001. On average, Alfred trades about 47,074 units every 79 days since 2003. As of 14 June 2023 he still owns at least 469,111 units of Lineage Cell Therapeutics Inc stock.

You can see the complete history of Mr. Kingsley stock trades at the bottom of the page.





Alfred Kingsley biography

Alfred D. Kingsley J.D. serves as Chairman of the Board of the Company. Mr. Kingsley has been general partner of Greenway Partners, L.P., a private investment firm, and President of Greenbelt Corp., a business consulting firm, since 1993. Greenbelt served as our financial advisor from 1998 until 2009. Mr. Kingsley also serves as a director of OncoCyte Corporation (OCX), a clinical-stage diagnostics company focused on novel, non-invasive blood-based tests for the early detection of cancer. From January 2017 to October 2018, Mr. Kingsley served as Executive Chairman of AgeX Therapeutics, Inc. (AGE), a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging. Mr. Kingsley also served as a director of Asterias Biotherapeutics, Inc. (AST) from 2012 until our acquisition of Asterias in March 2019. Mr. Kingsley was Senior Vice-President of Icahn and Company and its affiliated entities for more than 25 years. Mr. Kingsley holds a B.S. degree in economics from the Wharton School of the University of Pennsylvania and a J.D. degree and LLM in taxation from New York University Law School. Mr. Kingsley’s long career in corporate finance and mergers and acquisitions includes substantial experience in helping companies to improve their management and corporate governance, and to restructure their operations. Mr. Kingsley developed an intimate knowledge of our business in his role as our financial advisor before he joined our Board. Mr. Kingsley has been instrumental in structuring our equity and debt financings, and in the transition of our business focus into the field of stem cell technology, and the business acquisitions that have helped us expand the scope of our business.



How old is Alfred Kingsley?

Alfred Kingsley is 77, he's been the Chairman of the Board of Lineage Cell Therapeutics Inc since 2009. There are no older and 16 younger executives at Lineage Cell Therapeutics Inc.

What's Alfred Kingsley's mailing address?

Alfred's mailing address filed with the SEC is C/O LINEAGE CELL THERAPEUTICS, 2173 SALK AVENUE, SUITE 200, CARLSBAD, CA, 92008.

Insiders trading at Lineage Cell Therapeutics Inc

Over the last 5 years, insiders at Lineage Cell Therapeutics Inc have traded over $2,612,743 worth of Lineage Cell Therapeutics Inc stock and bought 7,879,334 units worth $8,569,904 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Alfred D Kingsley, and Brian M Culley. On average, Lineage Cell Therapeutics Inc executives and independent directors trade stock every 49 days with the average trade being worth of $212,992. The most recent stock trade was executed by Jill Ann Howe on 16 August 2024, trading 10,500 units of LCTX stock currently worth $9,345.



What does Lineage Cell Therapeutics Inc do?

biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.



What does Lineage Cell Therapeutics Inc's logo look like?

Lineage Cell Therapeutics Inc logo

Complete history of Mr. Kingsley stock trades at Oncocyte and Lineage Cell Therapeutics Inc

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
14 Jun 2023 OCX Oncocyte Corporation Alfred D Kingsley
Director
 Buy 30,000 $0.21 $6,300
14 Jun 2023
469,111 ↗
22 Dec 2022 OCX Oncocyte Corporation Alfred D Kingsley
Director
 Buy 25,000 $0.29 $7,250
22 Dec 2022
439,111 ↗
15 Aug 2022 OCX Oncocyte Corporation Alfred D Kingsley
Director
 Buy 10,000 $0.97 $9,700
15 Aug 2022
414,111 ↗
24 Jun 2022 OCX Oncocyte Corporation Alfred D Kingsley
Director
 Option 10,000 $1.02 $10,200
24 Jun 2022
394,111 ↗
23 Dec 2020 OCX Oncocyte Corporation Alfred D Kingsley
Director
 Option 66,508 $1.34 $89,121
23 Dec 2020
384,111 ↗
21 Dec 2020 OCX Oncocyte Corporation Alfred D Kingsley
Director
 Option 58,492 $1.34 $78,379
21 Dec 2020
326,155 ↗
22 Jun 2021 LCTX Lineage Cell Therapeutics Inc Alfred D Kingsley
Chairman
 Option 61,800 $2.20 $135,960
22 Jun 2021
5,470,245 ↗


Lineage Cell Therapeutics Inc executives and stock owners

Lineage Cell Therapeutics Inc executives and other stock owners filed with the SEC include: